Everest Organics Ltd. (BSE: 524790) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹221 Cr, it ranks #2,576 by market cap among the 6,137 Indian listed companies on FinBizNet, and #34 of 63 in Pharmaceuticals. At ₹251.00 (as of 25 Oct 2026), the share price is 53.2% below its 52-week high of ₹536.40 and 27.4% above its 52-week low of ₹197.00. The share price is down 43.3% over one year and down 23.4% over three months.
| Current Price | ₹251.00 |
|---|---|
| Market Cap | ₹221 Cr |
| BSE Code | 524790 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 44 |
| Return on Equity | 7.63% |
| Return on Assets | 3.76% |
| 52-Week Range | ₹197.00 – ₹536.40 |
| 1-Year Price Change | -43.3% |
| 3-Month Price Change | -23.4% |
| Beta (1Y) | 0.82 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | www.everestorganicsltd.com |
| Revenue | ₹48 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 2.3% |
| EPS (Basic) | ₹1.15 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Everest Organics Limited engages in the manufacture and sale of active pharmaceutical ingredients and its intermediaries in India. It is also involved in the manufacturing of bulk drugs-related business. The company exports its products. Everest Organics Limited was incorporated in 1993 and is based in Hyderabad, India.
1. Active Pharmaceuticals Ingredients (API) and Their Intermediates-This segment manufactures and sells pharmaceutical products. It offers active pharmaceutical ingredients and intermediaries.
1. Active Pharmaceutical Ingredients (API) and Their Intermediaries-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Everest Organics Ltd. | ₹221 Cr | 44 | 7.63% | ₹48 Cr | -43.3% |
Listed by market capitalisation. Ratios are shown for context only.
Everest Organics Ltd. is trading at ₹251.00, with a market capitalisation of ₹221 Cr.
Everest Organics Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Everest Organics Ltd. has a P/E of 44 and a return on equity of 7.63%.
Everest Organics Ltd. is listed on the BSE under the scrip code 524790.
Everest Organics Ltd.'s share price is down 43.3% over one year and down 23.4% over three months. Its 52-week range is ₹197.00 to ₹536.40.
In Q1 FY27, Everest Organics Ltd. reported revenue of ₹48 Cr and net profit of ₹1 Cr, with basic EPS of ₹1.15 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.